论文部分内容阅读
儿童急性淋巴细胞白血病(acute lymphoblastic leukemia,ALL)作为一种治愈率较高的疾病,化疗是其主要的治疗方法。CYP3A与MDR1作为决定药物代谢的关键基因,两者参与ALL化疗中大多数药物的代谢;两者基因多态性的表达会影响到药物代谢酶的活性进而影响药物代谢的效率。所以在日益提倡个体化治疗的今天,两者基因多态性的表达就直接关系到儿童ALL的治疗效果、药物毒副作用和预后。我们则可以根据两者基因多态性结合患儿的临床表现及其他实验室检查更为细致的划分出标危、中危和高危,采取不同的化疗方案,为实行个体化治疗提供理论依据。
As a disease with high cure rate, acute lymphoblastic leukemia (ALL) is the main treatment of chemotherapy. CYP3A and MDR1 are the key genes that determine drug metabolism. Both of them are involved in the metabolism of most drugs in ALL chemotherapy. The expression of these two genes will affect the activity of drug metabolizing enzymes and thus the efficiency of drug metabolism. Therefore, in today’s increasingly advocated individualized treatment, the expression of the two gene polymorphisms is directly related to the therapeutic effect of children ALL, drug side effects and prognosis. We can according to the two gene polymorphisms in children with clinical manifestations and other laboratory tests more detailed classification of the standard risk, risk and high risk, take a different chemotherapy, to provide a theoretical basis for the implementation of individualized treatment.